

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAMSUNG BIOEPIS CO., LTD., CELLTRION, INC., and
BIOCON BIOLOGICS INC.,
Petitioners,

v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner.

IPR2023-00884¹
Patent 11,253,572 B2

Before SUSAN L. C. MITCHELL, ROBERT A. POLLOCK, and
RYAN H. FLAX, *Administrative Patent Judges*.

FLAX, *Administrative Patent Judge*.

SECOND MODIFIED SCHEDULING ORDER
37 C.F.R. § 42.5(c)

¹ IPR2024-00260 and IPR2024-00298 were joined with IPR2023-00884.
See Papers 31 and 33.

IPR2023-00884
Patent 11,253,572 B2

Further to the original Scheduling Order entered November 24, 2023 (Paper 14), this Order sets modified due dates for the parties to act after institution of the proceeding. Modified due dates are shown underlined in the following Appendix. The modified due dates include those provided in the parties' stipulated changes to schedule (Paper 28) and a change in Due Date 8 (Oral Argument, if requested) to August 23, 2024. No other changes to the original Scheduling Order are ordered.

It is hereby

ORDERED that the schedule of the proceeding is modified as shown in the Appendix to this Order.

DUE DATE APPENDIX

DUE DATE 1	<u>February 23, 2024</u>
Patent Owner’s response to the petition	
Patent Owner’s motion to amend the patent	
DUE DATE 2	<u>May 17, 2024</u>
Petitioner’s reply to Patent Owner’s response to petition	
Petitioner’s opposition to motion to amend	
DUE DATE 3	<u>June 28, 2024</u>
Patent Owner’s sur-reply to reply	
Patent Owner’s reply to opposition to motion to amend (or Patent Owner’s revised motion to amend) ²	
DUE DATE 4	July 8, 2024
Request for oral argument (may not be extended by stipulation)	
DUE DATE 5	July 26, 2024
Petitioner’s sur-reply to reply to opposition to motion to amend	
Motion to exclude evidence	
DUE DATE 6	August 2, 2024
Opposition to motion to exclude	
Request for prehearing conference	
DUE DATE 7	August 9, 2024
Reply to opposition to motion to exclude	
DUE DATE 8	<u>August 23, 2024</u>
Oral argument (if requested)	

² If Patent Owner files neither a reply to Petitioner’s opposition to the MTA nor a revised MTA, *see* Section III(C) of the Original Scheduling Order.

IPR2023-00884
Patent 11,253,572 B2

For PETITIONER SAMSUNG BIOEPIS CO., LTD.:

Raymond N. Nimrod
Matthew A. Traupman
Landon Andrew Smith
QUINN EMANUEL URQUHART & SULLIVAN LLP
raynimrod@quinnemanuel.com
matthewtraupman@quinnemanuel.com
landonsmith@quinnemanuel.com
qe-samsungbioepis@quinnemanuel.com.

For PETITIONER CELLTRION, INC.:

Lora Green
Yahn Lin Chu
GEMINI LAW LLP
lgreen@geminilaw.com
fchu@geminilaw.com

For PETITIONER BIOCON BIOLOGICS INC.:

Paul Molino
Jeffrey Marx
Neil McLaughlin
Steven Birkos
Deanne Mazzochi
Thomas Ehrich
RAKOCZY MOLINO MAZZOCHI SIWIK LLP
paul@rmmslegal.com
jmarx@rmmslegal.com
nmclaughlin@rmmslegal.com
sbirkos@rmmslegal.com
dmazzochi@rmmslegal.com
tehrich@rmmslegal.com

IPR2023-00884
Patent 11,253,572 B2

For PATENT OWNER:

Adam R. Brausa
Rebecca Weires
Kira Davis
Daralyn Durie
MORRISON & FOERSTER LLP
ABrausa@mofocom
RWeires@mofocom
kiradavis@mofocom
ddurie@mofocom